COR-101
- Generic Name
- COR-101
Evaluation of Safety and Tolerability of COR-101 in Hospitalized Patients With Moderate to Severe COVID-19
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Corat Therapeutics Gmbh
- Target Recruit Count
- 45
- Registration Number
- NCT04674566
- Locations
- 🇩🇪
University Hospital Tübingen, Tübingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath